Home  |  Contact

UniProtKB/Swiss-Prot Q03518: Variant p.Ile393Val

Antigen peptide transporter 1
Gene: TAP1
Variant information

Variant position:  393
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LB/B
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Isoleucine (I) to Valine (V) at position 393 (I393V, p.Ile393Val).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Similar physico-chemical property. Both residues are medium size and hydrophobic.
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Polymorphism:  There are five common alleles; TAP1*01:01 (PSF1A), TAP1*02:01 (PSF1B), TAP1*03:01 (PSF1C), TAP1*01:04 and TAP1*x. The sequence of TAP1*01:01 is shown here.
Additional information on the polymorphism described.

Variant description:  In allele TAP1*02:01, allele TAP1*03:01, allele TAP1*04:01 and allele TAP1*x.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  393
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  808
The length of the canonical sequence.

Location on the sequence:   GLCLLGIMLWGSVSLTMVTL  I TLPLLFLLPKKVGKWYQLLE
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 808 Antigen peptide transporter 1
Transmembrane 389 – 409 Helical; Name=8
Domain 247 – 530 ABC transmembrane type-1


Literature citations

TAP1 alleles in insulin-dependent diabetes mellitus: a newly defined centromeric boundary of disease susceptibility.
Jackson D.G.; Capra J.D.;
Proc. Natl. Acad. Sci. U.S.A. 90:11079-11083(1993)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 61-808; VARIANTS VAL-393; LEU-518; GLY-697 AND GLN-708; POLYMORPHISM;

Allelic variants of the human putative peptide transporter involved in antigen processing.
Colonna M.; Bresnahan M.; Bahram S.; Strominger J.L.; Spies T.;
Proc. Natl. Acad. Sci. U.S.A. 89:3932-3936(1992)
Cited for: VARIANTS VAL-393 AND GLY-697; POLYMORPHISM;

TAP1 polymorphisms in several human ethnic groups: characteristics, evolution, and genotyping strategies.
Tang J.; Freedman D.O.; Allen S.; Karita E.; Musonda R.; Braga C.; Margolick J.; Kaslow R.A.;
Hum. Immunol. 62:256-268(2001)
Cited for: VARIANTS VAL-393; VAL-430; LEU-518; ILE-578; GLY-697 AND GLN-708; POLYMORPHISM;

Novel TAP1 polymorphisms in indigenous Zimbabweans: their potential implications on TAP function and in human diseases.
Lajoie J.; Zijenah L.S.; Faucher M.C.; Ward B.J.; Roger M.;
Hum. Immunol. 64:823-829(2003)
Cited for: VARIANTS SER-67; ARG-77; VAL-393; VAL-430; CYS-479; LEU-518; GLY-697 AND GLN-708; POLYMORPHISM;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.